$4.37
-0.07 (-1.58%)
Open$4.50
Previous Close$4.44
Day High$4.58
Day Low$4.20
52W High$7.75
52W Low$1.32
Volume—
Avg Volume209.0K
Market Cap218.09M
P/E Ratio—
EPS$-2.24
SectorBiotechnology
Analyst Ratings
Strong Buy
12 analysts
Price Target
+174.8% upside
Current
$4.37
$4.37
Target
$12.01
$12.01
$8.14
$12.01 avg
$13.09
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 368.79M | 346.38M | 334.67M |
| Net Income | 5.96M | 4.54M | 4.70M |
| Profit Margin | 1.6% | 1.3% | 1.4% |
| EBITDA | 7.81M | 7.32M | 6.13M |
| Free Cash Flow | 4.41M | 4.25M | 6.96M |
| Rev Growth | +17.9% | -7.3% | +7.0% |
| Debt/Equity | 0.83 | 0.86 | 0.78 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $251.64 | -1.05% | 118.2 | 429.58B |
| AMGN | Amgen Inc | $362.12 | +0.44% | 24.8 | 193.10B |
| GILD | Gilead Sciences Inc | $126.34 | +0.01% | 17.1 | 157.21B |
| VRTX | Vertex Pharmaceuticals Inc | $496.73 | -0.58% | 28.1 | 121.87B |
| REGN | Regeneron Pharmaceuticals | $623.54 | -1.31% | 15.0 | 66.35B |
| ALNY | Alnylam Pharmaceuticals Inc | $301.03 | +2.56% | 69.3 | 39.97B |